Succipro, a spin-off created in 2022 as a result of research from IRB CatSud (the new name that the current IISPV will adopt from 2026), has joined the business and innovation platform Catalonia.health. This step will help the company connect with other organisations in the Catalan biomedical sector, create synergies, share knowledge and speed up the development of its products.
Succipro focuses on developing new therapeutic strategies based on succinate modulation, with the aim of addressing inflammatory and metabolic diseases that affect millions of people. All of this is explained in this video.
At the moment, Succipro is developing a drug for the treatment of Inflammatory Bowel Disease (IBD). It is currently in the preclinical phase and shows very promising initial results. Succipro’s drugs also have the potential to treat other complex diseases of high clinical relevance, such as diabetes or certain types of cancer, where inflammation and metabolism play an important role.
At Succipro, the team works every day to improve the quality of life of people living with these conditions. The company is strongly committed to developing therapies that address real and personalised problems in patients. This approach follows the principles of personalised medicine, designing molecules with proper scientific and methodological validation to solve problems that are not yet fully addressed.
For Succipro, joining Catalonia.health is a “strategic decision that will allow the company to build connections with other organisations in the Catalan biomedical sector”. This collaboration is expected to help create synergies, share knowledge and accelerate the development of its products. This link between science, business and health is seen as essential to position Catalonia as an international reference in biomedicine.
More information: https://www.succipro.com/ https://www.iispv.cat/
Facebook 
Mail 
WhatsApp 